Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer

References

• AssiHAKhouryKEDboukHKhalilLEMouhieddineTHEl SaghirNSEpidemiology and prognosis of breast cancer in young womenJ Thorac Dis20135S2S823819024
   PubMed Web of Science ®Google Scholar
• ThomssenCMarschnerNUntchMABC1 Consensus Conference – a German Perspective: First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011Breast Care (Basel)20127525922553474
   PubMed Web of Science ®Google Scholar
• TruongPTOlivottoIAWhelanTJClinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapyCMAJ20041701263127315078851
   PubMed Web of Science ®Google Scholar
• KroenkeCHQuesenberryCKwanMLSweeneyCCastilloACaanBJSocial networks, social support, and burden in relationships, and mortality after breast cancer diagnosis in the Life After Breast Cancer Epidemiology (LACE) studyBreast Cancer Res Treat201313726127123143212
   PubMed Web of Science ®Google Scholar
• PetrieWLoganJDeGrasseCResearch review of the supportive care needs of spouses of women with breast cancerOncol Nurs Forum2001281601160711759307
   PubMedGoogle Scholar
• García-EstévezLTusquetsIAlvarezISupportive care for patients with early breast cancerClin Transl Oncol201012324220080469
   PubMed Web of Science ®Google Scholar
• FreedmanOAmirEZimmermannCClemonsMFilling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trialsSupport Care Cancer20111931532221203780
   PubMed Web of Science ®Google Scholar
• VialePHChemotherapy and cutaneous toxicities: implications for oncology nursesSemin Oncol Nurs20062214415116893743
   PubMedGoogle Scholar
• GutzmerRWollenbergAUgurelSHomeyBGanserAKappACutaneous side effects of new antitumor drugs: clinical features and managementDtsch Arztebl Int201210913314022419954
   PubMed Web of Science ®Google Scholar
• HartmannJTHaapMKoppHGLippHPTyrosine kinase inhibitors – a review on pharmacology, metabolism and side effectsCurr Drug Metab20091047048119689244
   PubMed Web of Science ®Google Scholar
• Webster-GandyJDHowCHarroldKPalmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centreEur J Oncol Nurs20071123824617350337
   PubMed Web of Science ®Google Scholar
• KumarSJuresicEBartonMShafiqJManagement of skin toxicity during radiation therapy: a review of the evidenceJ Med Imaging Radiat Oncol20105426427920598015
   PubMed Web of Science ®Google Scholar
• HaleyACCalahanCGandhiMWestDPRademakerALacoutureMESkin care management in cancer patients: an evaluation of quality of life and tolerabilitySupport Care Cancer20111954555420336328
   PubMed Web of Science ®Google Scholar
• MASCCCaring for your skin, hait and nails whenon “targeted therapies”2011 Available from: (http://www.mascc.org/assets/documents/skin_toxicity_egfri_patientbrochure.pdf)Accessed April 10, 2014
   Google Scholar
• American Cancer SocietyTargeted therapy2013 Available from:(http://www.cancer.org/acs/groups/cid/documents/webcontent/003024-pdf.pdf)Accessed April 10, 2014
   Google Scholar
• DrenoBBensadounRJHumbertPAlgorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncologyJ Eur Acad Dermatol Venereol2013271071108023368717
   PubMed Web of Science ®Google Scholar
• PotthoffKHofheinzRHasselJCInterdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinionAnn Oncol20112252453520709812
   PubMed Web of Science ®Google Scholar
• PatriziAVenturiMDikaEMaibachHTacchettiPBrandiGCutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effectsCutan Ocul Toxicol2014331623638756
   PubMed Web of Science ®Google Scholar
• MateusCRobertCNew drugs in oncology and skin toxicityRev Med Interne200930401410 French19299041
   PubMed Web of Science ®Google Scholar
• LacoutureMEMeloskyBLCutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspectiveSkin Therapy Lett2007121517762902
   PubMedGoogle Scholar
• Galimont-CollenAFVosLELavrijsenAPOuwerkerkJGelderblomHClassification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitorsEur J Cancer20074384585117289377
   PubMed Web of Science ®Google Scholar
• LacoutureMEAnadkatMJBensadounRJClinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesSupport Care Cancer2011191079109521630130
   PubMed Web of Science ®Google Scholar
• AghaRKinahanKBennettCLLacoutureMEDermatologic challenges in cancer patients and survivorsOncology (Williston Park)20072114621472 discussion 1473, 1476, 1481 passim18077993
   PubMed Web of Science ®Google Scholar
• ZhangZRiviereJEMonteiro-RiviereNAEvaluation of protective effects of sodium thiosulfate, cysteine, niacinamide and indomethacin on sulfur mustard-treated isolated perfused porcine skinChem Biol Interact1995962492627750164
   PubMed Web of Science ®Google Scholar
• NamaziMRNicotinamide in dermatology: a capsule summaryInt J Dermatol2007461229123118173513
   PubMed Web of Science ®Google Scholar
• BissettDTopical niacinamide and barrier enhancementCutis200270812 discussion 21–2312498532
   PubMed Web of Science ®Google Scholar
• GehringWNicotinic acid/niacinamide and the skinJ Cosmet Dermatol20043889317147561
   PubMedGoogle Scholar
• OtteNBorelliCKortingHCNicotinamide – biologic actions of an emerging cosmetic ingredientInt J Cosmet Sci20052725526118492206
   PubMedGoogle Scholar
• TannoOOtaYKitamuraNKatsubeTInoueSNicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrierBr J Dermatol200014352453110971324
   PubMed Web of Science ®Google Scholar
• DharajiyaNChoudhuryBKBacsiABoldoghIAlamRSurSInhibiting pollen reduced nicotinamide adenine dinucleotide phosphate oxidase-induced signal by intrapulmonary administration of antioxidants blocks allergic airway inflammationJ Allergy Clin Immunol200711964665317336614
   PubMed Web of Science ®Google Scholar
• WhiteSDRosychukRAReinkeSIParadisMUse of tetracycline and niacinamide for treatment of autoimmune skin disease in 31 dogsJ Am Vet Med Assoc1992200149715001535346
   PubMed Web of Science ®Google Scholar
• FabbrociniGCantelliMMonfrecolaGTopical nicotinamide for seborrheic dermatitis: an open randomized studyJ Dermatolog Treat20142524124523763270
   PubMed Web of Science ®Google Scholar
• NamaziMRNicotinamide as a potential addition to the anti-atopic dermatitis armamentariumInt Immunopharmacol20044670971215135312
   PubMed Web of Science ®Google Scholar
• Cosmetic Ingredient review expert panelFinal report of safety assessment of niacinamide and niacinInt J Toxicol200524Suppl 5131
   Google Scholar
• FinlayAYKhanGKDermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical useClin Exp Dermatol1994192102168033378
   PubMed Web of Science ®Google Scholar
• LewisVFinlayAY10 years experience of the Dermatology Life Quality Index (DLQI)J Investig Dermatol Symp Proc20049169180
   PubMed Web of Science ®Google Scholar
• NijstenTMeadsDMMcKennaSPDimensionality of the dermatology life quality index (DLQI): a commentaryActa Derm Venereol200686284285 author reply 285–28616710607
   PubMed Web of Science ®Google Scholar
• FinlayAYBasraMKPiguetVSalekMSDermatology life quality index (DLQI): a paradigm shift to patient-centered outcomesJ Invest Dermatol20121322464246522592153
   PubMed Web of Science ®Google Scholar
• HongboYThomasCLHarrisonMASalekMSFinlayAYTranslating the science of quality of life into practice: What do dermatology life quality index scores mean?J Invest Dermatol200512565966416185263
   PubMed Web of Science ®Google Scholar
• BasraMKFenechRGattRMSalekMSFinlayAYThe Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical resultsBr J Dermatol2008159997103518795920
   PubMed Web of Science ®Google Scholar
• CraigBMBusschbachJJSalomonJAModeling ranking, time trade-off, and visual analog scale values for EQ-5D health states: a review and comparison of methodsMed Care20094763464119433996
   PubMedGoogle Scholar
• NamaziMRNicotinamide-containing sunscreens for use in Australasian countries and cancer-provoking conditionsMed Hypotheses20036054454512615518
   PubMed Web of Science ®Google Scholar
• SurjanaDHallidayGMDamianDLNicotinamide enhances repair of ultraviolet radiation-induced DNA damage in human keratinocytes and ex vivo skinCarcinogenesis2013341144114923349012
   PubMed Web of Science ®Google Scholar
• GuptaNSaleemAKotzBKötzBCarbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patientsClin Cancer Res2006123115312316707610
   PubMed Web of Science ®Google Scholar
• GrangePARaingeaudJCalvezVDupinNNicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kappaB and MAPK pathwaysJ Dermatol Sci20095610611219726162
   PubMed Web of Science ®Google Scholar
• MonfrecolaGGaudielloFCirilloTFabbrociniGBalatoALemboSNicotinamide downregulates gene expression of interleukin-6, interleukin-10, monocyte chemoattractant protein-1, and tumour necrosis factor-alpha gene expression in HaCaT keratinocytes after ultraviolet B irradiationClin Exp Dermatol20133818518823397947
   PubMed Web of Science ®Google Scholar
• Cosmetic Ingredient Review Expert PanelFinal report of the safety assessment of niacinamide and niacinInt J Toxicol200524Suppl 5131
   Google Scholar
• KnipMDouekIFMooreWPSafety of high-dose nicotinamide: a reviewDiabetologia2000431337134511126400
   PubMed Web of Science ®Google Scholar
• VasanthaJSoundararajanPVanitharaniNSafety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysisIndian J Nephrol20112124524922022084
   PubMedGoogle Scholar
• PigottKDischeSSaundersMIShort communication: the addition of carbogen and nicotinamide to a palliative fractionation schedule for locally advanced breast cancerBr J Radiol1995682152187537598
   PubMed Web of Science ®Google Scholar
• RuddockMWHirstDGNicotinamide relaxes vascular smooth muscle by inhibiting myosin light chain kinase-dependent signaling pathways: implications for anticancer efficacyOncol Res20041448348915559762
   PubMed Web of Science ®Google Scholar
• HoeslyFJBakerSGGunawardaneNDCotliarJACapecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literatureArch Dermatol20111471418142322184763
   PubMedGoogle Scholar
• KhandanpourCDührsenURöthAHand-Foot syndrome: Common presentation in an uncommon situationEur J Haematol20139147223859621
   PubMed Web of Science ®Google Scholar
• YokomichiNNagasawaTColer-ReillyAPathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal DoxorubicinHum Cell20132681823386177
   PubMed Web of Science ®Google Scholar